

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Blissco Cannabis Corp.** (the "Issuer" or the "Company" or "Blissco").

Trading Symbol: **BLIS**

Number of Outstanding Listed Securities: **107,142,670**

Date: **May 6, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**Blissco has signed a distribution and supply agreement with National Cannabis Distribution. The supply agreement with Blissco contains both whole dried flower and pre-rolled cannabis products with the option to include oils, extracts, edibles and topicals in the future.**

---

**The Company has successfully manufactured premium CBD oil for R&D purposes by running hemp through extraction cycles.**

**The Company submitted a licence amendment to Health Canada that will enable Blissco to sell cannabis oil products to provincially authorized distributors and retailers and to registered medical patients.**

2. Provide a general overview and discussion of the activities of management.

**Blissco management has been overseeing and managing the progress of the business and operations described in 1 above.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**The Company has successfully manufactured premium CBD oil for R&D purposes by running hemp through extraction cycles.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Blissco has signed a distribution and supply agreement with National Cannabis Distribution. The supply agreement with Blissco contains both whole dried flower and pre-rolled cannabis products with the option to include oils, extracts, edibles and topicals in the future.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

8. Describe the acquisition of new customers or loss of customers.

**None.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**The Company has hired additional Production & Packaging and Labelling and Fulfilment Staff during the month of April 2019.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>
Common Shares	100,000	Warrant exercise	25,000
Common Shares	250,000	Warrant exercise	62,500
Common Shares	30,000	Warrant exercise	7,500
Common Shares	25,000	Warrant exercise	6,250
Common Shares	100,000	Warrant exercise	25,000
Common Shares	125,000	Warrant exercise	31,250
Common Shares	125,000	Warrant exercise	31,250
Common Shares	70,000	Warrant exercise	17,500
Common Shares	100,000	Warrant exercise	25,000
Common Shares	150,000	Warrant exercise	37,500
Common Shares	50,000	Warrant exercise	12,500
Common Shares	125,000	Warrant exercise	31,250
Common Shares	50,000	Warrant exercise	12,500
Common Shares	500,000	Warrant exercise	125,000
Common Shares	125,000	Warrant exercise	31,250
Common Shares	200,000	Warrant exercise	50,000
Common Shares	100,000	Warrant exercise	25,000
Common Shares	200,000	Warrant exercise	50,000
Common Shares	50,000	Warrant exercise	12,500

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**None.**

16. Provide details of any changes in directors, officers or committee members.

**None.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**None.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2019

Damian Kettlewell  
Name of Director or Senior  
Officer

"Damian Kettlewell"  
Signature  
Chief Executive Officer  
Official Capacity

<b><i>Issuer Details</i></b> Name of Issuer <b>Blissco Cannabis Corp.</b>	For Month End <b>April 30, 2019</b>	Date of Report YY/MM/D <b>19/05/06</b>
Issuer Address <b>PO Box 32031 Walnut Grove</b>		
City/Province/Postal Code <b>Langley, BC V1M 2M3</b>	Issuer Fax No. 1(877) 451- 6927	Issuer Telephone No. ( )
Contact Name <b>Damian Kettlewell</b>	Contact Position <b>Chief Executive Officer</b>	Contact Telephone No. (604) 484-9119